Ladenburg Thalmann Financial Services’s Innate Pharma IPHA Stock Holding History

Ladenburg Thalmann Financial Services’s Portfolio IPHA Stock Details IPHA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	$2K	Buy	+15	New	+$92	﹤0.01%	5071

Other funds holding IPHA

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Maven Securities St Helier, Jersey $5.2B AUM 44.01% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

OAM

Oxford Asset Management Oxford, United Kingdom $232M AUM 31% 1-Year Est. Return

OMC

Old Mission Capital Chicago, Illinois $6.3B AUM 14.68% 1-Year Est. Return

FIA

FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return

SPIA

Steward Partners Investment Advisory New York $19.6B AUM 22.89% 1-Year Est. Return

Ladenburg Thalmann Financial Services's IPHA Position: Q4 2019 in Review

Ladenburg Thalmann Financial Services opened a new position in Innate Pharma (IPHA) in Q4 2019: 15 shares worth $2K. The stake represents ﹤0.01% of the portfolio and ranks #5071 among its holdings.

12 funds tracked by Wall St. Rank hold IPHA as of Q4 2019.

Ladenburg Thalmann Financial Services held 15 shares of Innate Pharma worth $2K as of Q4 2019.
Innate Pharma was a new Ladenburg Thalmann Financial Services position in Q4 2019.
Innate Pharma made up ﹤0.01% of Ladenburg Thalmann Financial Services's portfolio in Q4 2019, its #5071 holding.
12 funds tracked by Wall St. Rank held Innate Pharma as of Q4 2019.

Based on Ladenburg Thalmann Financial Services's 13F filing for Q4 2019, filed 14 Feb 2020.